Bharat Biotech's homegrown COVID-19 vaccine has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Indian company said on Wednesday.
The interim analysis was based on 43 recorded cases of COVID-19 in the trial of 25,800 participants, conducted in partnership with the Indian government's medical research body.
Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6%, the company said.
India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness.
India's vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca.
Earlier this week, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN.
Kuwait strongly condemns repeated Houthi attacks on ships in Red Sea
Southern China faces torrential rain, flood risk after Typhoon Noul hits land
India's youth protests end as Modi's education minister quits
Vehicle mows down crowd at Berlin Pride festival, killing one
Rescuers scour South China Sea for 17 missing after Vietnamese vessel sinks
